Last reviewed · How we verify
NoNO-42
NoNO-42 is a nitric oxide (NO) donor compound designed to increase nitric oxide bioavailability in target tissues.
At a glance
| Generic name | NoNO-42 |
|---|---|
| Sponsor | NoNO Inc. |
| Target | Nitric oxide pathway / soluble guanylate cyclase |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The drug releases or facilitates the production of nitric oxide, a signaling molecule that plays key roles in vasodilation, anti-inflammatory responses, and cellular regulation. By enhancing NO availability, NoNO-42 aims to improve endothelial function and reduce pathological inflammation in disease states.
Approved indications
Common side effects
Key clinical trials
- NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy (PHASE2)
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
- A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NoNO-42 CI brief — competitive landscape report
- NoNO-42 updates RSS · CI watch RSS
- NoNO Inc. portfolio CI